Skip to main content

What's a sure-fire way to make your stock price soar? Invest in technology, Jim Cramer told his Mad Money viewers Wednesday. You don't need to be a tech company to use technology to trounce your competition, Cramer added, as several companies proved today.

Technology is at the core of Home Depot's (HD) - Get Home Depot Inc. (The) Report continued growth, and it's why the company announced today that it aims to hire another 1,000 tech professionals to help it pull even further away from rivals like Lowe's (LOW) - Get Lowe's Companies Inc. Report .

Railroad CSX (CSX) - Get CSX Corporation Report is another stealth tech company. CSX saw its load volumes decrease this quarter, but was still able to crush earnings estimates thanks to increased efficiencies that stemmed from -- you guessed it -- technology. Shares of CSX were up 7.8% on the day.

America's oil renaissance is powered almost exclusively by technology, as companies like Schlumberger (SLB) - Get Schlumberger N.V. Report and Core Labs (CLB) - Get Core Laboratories N.V. Report are breathing new life into once forgotten wells. Nucor (NUE) - Get Nucor Corporation Report has a similar leadership position in the steel industry thanks to technology, and that company will only benefit more that President Trump's tariffs put the market on a more level playing field.

Finally, there's IBM (IBM) - Get International Business Machines Corporation Report a tech company that's all about tech, but sadly still has much of the wrong tech. Only half of IBM is in the fast-growing segments that customers crave, which is in stark contrast to Amazon (AMZN) - Get Inc. Report , which seems to be in demand practically everywhere.

Cramer and the AAP team are trimming Illinois Tool Works (ITW) - Get Illinois Tool Works Inc. Report and Danaher (DHR) - Get Danaher Corporation Report . Find out what they're telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.

Executive Decision: CyrusOne 

For his "Executive Decision" segment, Cramer sat down with Gary Wojtaszek, president and CEO of CyrusOne (CONE) - Get CyrusOne Inc Report , the data center REIT with a 3.75% yield and shares that have dropped 14% in 2018, as REITs have fallen out of favor on Wall Street.

Wojtaszek said he can't control how shares trade on Wall Street, but he can control the company's execution. CyrusOne just posted its strongest quarter ever and continues to lead the industry higher.

Wojtaszek added that CyrusOne continues to follow their customers, which led them to the $442 million acquisition of Zenium, one of the largest data center operators in London and Frankfort. Closer to home, he said, their recent land purchase in Atlanta was also based on customer demand and putting data centers where customers need them.

CyrusOne now has all of the major cloud providers as customers.

Cramer said while REITs are currently out of favor on Wall Street, there was also a time when being a REIT was a blessing.

Don't Bet Against the Banks

Are the banks signaling the economy has stalled and a recession is looming? That's what the bears would have you believe, Cramer told viewers, but he's not buying it.

Cramer admitted this quarter's bank earnings weren't fantastic, but they were good, and "good" isn't a sign there's lower loan demand or that the banks aren't willing to lend.

The banking industry is alive a well, Cramer said, and they're actually doing what they should be doing, lending at the rate of GDP growth and not taking unnecessary risks. Add to that the fact the banks have the best balance sheets they've had in decades and things are looking quite rosy indeed.

Scroll to Continue

TheStreet Recommends

If the banks were lending at a higher rate, these same bears would be sounding the alarm about reckless behavior masking slowing growth and yes, a looming recession. But instead, the banks are being responsible, the exact things we've been asking them to do since the financial crisis.

Over on Real Money, Cramer says he's not buying the "tax cuts not bringing about growth" thesis. Get more of his insights with a free trial subscription to Real Money.

Don't Ignore the Risks 

Investors always need to understand the risks of what they're buying, Cramer reminded viewers, as he dug into the surprise, but totally foreseeable, 35% decline in shares of Acacia Communications (ACIA) - Get Acacia Communications, Inc. Report on Monday.

On Monday we learned that the Commerce Department issued a ban on doing business with the Chinese telco operator ZTE, which has been accused of selling equipment to Iran against international sanctions. ZTE, it turns out, is Acacia's largest customer, accounting for 35% of the company's sales.

This should not have come as a surprise to investors, Cramer said, as the company outlined the risks in its annual report. In fact, the high percentage of revenues stemming from only a handful of customers was the company's number one concern. They even called out ZTE by name, noting that Acacia was already only able to sell to ZTE under a temporary license from the Commerce Department.

Investors should always read the risk factors section of a company's annual report and take note of a company's customer base, the size and location of that base and the company's relationship with them. In the case of Acacia, the concentration was clearly there, with a risky customer, in China at a time when the White House is making a strong statement on trade.

Executive Decision: Revance Therapeutics 

In his second "Executive Decision" segment, Cramer also sat down with Dan Browne, co-founder, president and CEO of Revance Therapeutics (RVNC) - Get Revance Therapeutics Inc. Report , the biotech that's actively developing an alternative to Allergan's (AGN) - Get Allergan plc Report wildly successful Botox.

Browne said that Revance is on track to file for FDA approval for "RT002" next year, which would likely put their product on the market by early 2020. He said what makes RT002 different from Botox is the duration of the dose, which the data is indicating lasts a full six months for frown lines. Revance has plans to explore therapeutic applications for RT002, just like Allergan has.

Browne added that while RT002 is distinctly different from the formulation of Botox, the drug will be made completely in the U.S., which will give his company the same profit margins as their larger rival.

When asked whether they have enough cash on hand to see RT002 to market, Browne said that Revance is well capitalized and they have a number of catalysts ahead that would allow them to raise additional capital if needed. 

Lightning Round

In the Lightning Round, Cramer was bullish on Dropbox (DBX) - Get Dropbox Inc Report , Spotify (SPOT) - Get Spotify Technology S.A. Report , Myriad Genetics (MYGN) - Get Myriad Genetics Inc. Report , Skechers USA (SKX) - Get Skechers U.S.A. Inc. Report , Enterprise Products Partners (EPD) - Get Enterprise Products Partners L.P. Report and American Water Works (AWK) - Get American Water Works Company Inc. Report .

Cramer was bearish on Worthington Industries (WOR) - Get Worthington Industries Inc. Report , Qualcomm (QCOM) - Get QUALCOMM Incorporated Report , Kratos Defense & Security (KTOS) - Get Kratos Defense & Security Solutions Inc. Report and YY (YY) - Get JOYY Inc. Report .

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Cramer's Action Alerts PLUS had a position in ITW, DHR, SLB, NUE, AMZN.